Toru Higuchi

1.9k total citations
71 papers, 1.3k citations indexed

About

Toru Higuchi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Toru Higuchi has authored 71 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Toru Higuchi's work include Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Treatment and Pharmacology (8 papers). Toru Higuchi is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Treatment and Pharmacology (8 papers). Toru Higuchi collaborates with scholars based in Japan, United States and United Kingdom. Toru Higuchi's co-authors include Frank Uhlmann, V.L. Katis, Matt Sullivan, Kazuya Yasuhara, A. F. L. Hyde, Andrés Jaramillo, M. H. Bulmer, J. Carey, David N. Petley and Thalachallour Mohanakumar and has published in prestigious journals such as Nature, Cell and Journal of Clinical Oncology.

In The Last Decade

Toru Higuchi

65 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Toru Higuchi Japan	20	523	278	195	165	151	71	1.3k
Ming Yi China	18	347 0.7×	109 0.4×	114 0.6×	47 0.3×	12 0.1×	51	966
Hiroyuki Araki Japan	18	318 0.6×	32 0.1×	50 0.3×	116 0.7×	139 0.9×	75	848
Aichun Liu China	18	260 0.5×	28 0.1×	25 0.1×	235 1.4×	46 0.3×	77	881
Toshimi Satoh Japan	20	332 0.6×	23 0.1×	110 0.6×	284 1.7×	21 0.1×	105	1.4k
Tetsuo Ueno Japan	10	255 0.5×	41 0.1×	144 0.7×	50 0.3×	16 0.1×	36	853
Yasushi Kojima Japan	27	766 1.5×	106 0.4×	605 3.1×	1.0k 6.2×	35 0.2×	133	2.6k
Thomas Hiller Germany	15	145 0.3×	23 0.1×	91 0.5×	81 0.5×	10 0.1×	49	950
Xiaohua Zhu China	24	273 0.5×	15 0.1×	93 0.5×	334 2.0×	28 0.2×	109	1.5k
Wenhuan Kuang China	11	565 1.1×	163 0.6×	40 0.2×	100 0.6×	23 0.2×	25	1.0k
Robert C. Briggs United States	20	803 1.5×	108 0.4×	35 0.2×	278 1.7×	34 0.2×	60	1.4k

Countries citing papers authored by Toru Higuchi

Since Specialization

Citations

This map shows the geographic impact of Toru Higuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toru Higuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toru Higuchi more than expected).

Fields of papers citing papers by Toru Higuchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toru Higuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toru Higuchi. The network helps show where Toru Higuchi may publish in the future.

Co-authorship network of co-authors of Toru Higuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Toru Higuchi. A scholar is included among the top collaborators of Toru Higuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toru Higuchi. Toru Higuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamashita, Toshinari, Shigehira Saji, Toshimi Takano, et al.. (2025). Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. Journal of Clinical Oncology. 43(11). 1302–1313. 5 indexed citations

Yamashita, Toshinari, Shigehira Saji, Toshimi Takano, et al.. (2024). Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).. Journal of Clinical Oncology. 42(16_suppl). 1007–1007. 2 indexed citations

Kosmala, Aleksander, Toru Higuchi, Philipp E. Hartrampf, et al.. (2023). CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie. Nuklearmedizin - NuclearMedicine. 62(2). 95–95. 1 indexed citations

Higuchi, Toru, et al.. (2023). P44-1 A study of 11 patients treated with trastuzumab deruxtecan including those with interstitial lung disease. Annals of Oncology. 34. S1458–S1459.

Niwa, Hidekazu, et al.. (2022). Prevalence of equine proliferative enteropathy in Hidaka district, Hokkaido, over five seasons. Journal of Equine Science. 33(4). 71–74. 1 indexed citations

Shimomura, Akihiko, Masayuki Yoshida, Takashi Kubo, et al.. (2022). Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer. Breast Cancer Research and Treatment. 197(3). 593–602.

Taniguchi, Tomohiko, Toru Higuchi, Junichi Tazaki, Naritatsu Saito, & Takeshi Kimura. (2017). Successful Percutaneous Transcatheter Angioplasty of Radial Artery in Thromboangiitis Obliterans (Buerger’s Disease). JACC: Cardiovascular Interventions. 10(22). e205–e206. 3 indexed citations

Fujii, Takaaki, Reina Yajima, Sasagu Kurozumi, et al.. (2016). Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma. Anticancer Research. 36(10). 5481–5486. 33 indexed citations

Takada, Mamoru, Toru Higuchi, Hiroyuki Takei, et al.. (2013). Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. BMC Cancer. 13(1). 241–241. 22 indexed citations

10.

Iwakiri, Ryuichi, Yasuhisa Sakata, Daisuke Yamaguchi, et al.. (2012). Endoscopic Reflux Esophagitis and Helicobacter pylori Infection in Young Healthy Japanese Volunteers. Digestion. 86(1). 55–58. 29 indexed citations

11.

Nakamura, Noriko, et al.. (2011). Boiling Heat Transfer and Flow Characteristics of Liquid Nitrogen in Helically Coiled Tube. JAPANESE JOURNAL OF MULTIPHASE FLOW. 24(5). 567–576. 4 indexed citations

12.

Nakamura, Noriko, et al.. (2011). . JAPANESE JOURNAL OF MULTIPHASE FLOW. 24(5). 567–576. 5 indexed citations

13.

Ishida, Waka, et al.. (2009). Systemic overexpression of IFN- and IL-5 exacerbates early phase reaction and conjunctival eosinophilia, respectively, in experimental allergic conjunctivitis. British Journal of Ophthalmology. 93(12). 1680–1685. 2 indexed citations

14.

Higuchi, Toru. (2008). Electronic structure of multiferroic BiFeO3 by resonant soft-x-ray emission spectroscopy. eScholarship (California Digital Library). 1 indexed citations

15.

Higuchi, Toru, Takahiro Maruyama, Andrés Jaramillo, & Thalachallour Mohanakumar. (2005). Induction of Obliterative Airway Disease in Murine Tracheal Allografts by CD8+ CTLs Recognizing a Single Minor Histocompatibility Antigen. The Journal of Immunology. 174(4). 1871–1878. 18 indexed citations

16.

Smith, Craig R., Andrés Jaramillo, Kim C. Lu, et al.. (2001). PREVENTION OF OBLITERATIVE AIRWAY DISEASE IN HLA-A2-TRANSGENIC TRACHEAL ALLOGRAFTS BY NEUTRALIZATION OF TUMOR NECROSIS FACTOR1. Transplantation. 72(9). 1512–1518. 28 indexed citations

17.

Shiroki, Ryoichi, et al.. (1997). Quadruple immunosuppressive therapy with low-dose cyclosporine provides superior kidney transplant outcome using grafts of non-heart-beating uncontrolled cadavers. Transplantation Proceedings. 29(8). 3571–3573. 3 indexed citations

18.

Okada, Shoshiro, et al.. (1992). Influence of Prostaglandin E₁ on Slight Proteinuria in Non-Azotaemic Diabetics. Journal of International Medical Research. 20(1). 94–97. 4 indexed citations

19.

Makino, Hirofumi, et al.. (1985). Influence of prostaglandin E1* * Prostandin® - Prostagladin E1 - Ono Pharmaceutical Co. Ltd., Osaka, Japan. on proteinuria of diabetic nephropathy. A case report. Clinical Trials. 22(3). 263–266. 3 indexed citations

20.

Higuchi, Toru, et al.. (1981). Enhanced renal clearance of uric acid in hepatic cirrhosis.. PubMed. 17(11). 1015–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact